Hilde Bigler

437 total citations
7 papers, 377 citations indexed

About

Hilde Bigler is a scholar working on Genetics, Hematology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Hilde Bigler has authored 7 papers receiving a total of 377 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Genetics, 3 papers in Hematology and 2 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Hilde Bigler's work include Hemoglobinopathies and Related Disorders (3 papers), Iron Metabolism and Disorders (3 papers) and Pharmaceutical Economics and Policy (2 papers). Hilde Bigler is often cited by papers focused on Hemoglobinopathies and Related Disorders (3 papers), Iron Metabolism and Disorders (3 papers) and Pharmaceutical Economics and Policy (2 papers). Hilde Bigler collaborates with scholars based in Switzerland, Italy and United States. Hilde Bigler's co-authors include Romain Séchaud, Daniele Alberti, Renzo Galanello, Antonio Piga, M.C. Rouan, H. A. Dieterich, Sujata Vaidyanathan, Marie‐Noëlle Bizot, William P. Dole and Dan Howard and has published in prestigious journals such as Clinical Pharmacokinetics, The Journal of Clinical Pharmacology and Current Medical Research and Opinion.

In The Last Decade

Hilde Bigler

7 papers receiving 358 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hilde Bigler Switzerland	6	246	224	67	56	47	7	377
Paulo Caleb Júnior Lima Santos Brazil	12	60 0.2×	75 0.3×	20 0.3×	47 0.8×	21 0.4×	36	286
Mark Allison United States	9	68 0.3×	83 0.4×	30 0.4×	25 0.4×	36 0.8×	14	514
Marion Dahlke Switzerland	12	21 0.1×	46 0.2×	37 0.6×	132 2.4×	32 0.7×	31	436
Loeckie De Zwart Belgium	12	115 0.5×	50 0.2×	69 1.0×	9 0.2×	11 0.2×	23	449
Arvind B. Rege United States	12	88 0.4×	210 0.9×	91 1.4×	7 0.1×	12 0.3×	16	503
David Mathews United States	8	35 0.1×	37 0.2×	37 0.6×	51 0.9×	17 0.4×	9	267
Mark Veerman United States	7	36 0.1×	46 0.2×	61 0.9×	10 0.2×	22 0.5×	10	368
R VANSCHAIK Netherlands	5	60 0.2×	76 0.3×	137 2.0×	6 0.1×	12 0.3×	6	386
Mohammad Saleh Jordan	9	25 0.1×	55 0.2×	38 0.6×	19 0.3×	13 0.3×	36	223
Klaus Moerike Germany	5	33 0.1×	42 0.2×	124 1.9×	146 2.6×	66 1.4×	6	582

Countries citing papers authored by Hilde Bigler

Since Specialization

Citations

This map shows the geographic impact of Hilde Bigler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hilde Bigler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hilde Bigler more than expected).

Fields of papers citing papers by Hilde Bigler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hilde Bigler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hilde Bigler. The network helps show where Hilde Bigler may publish in the future.

Co-authorship network of co-authors of Hilde Bigler

This figure shows the co-authorship network connecting the top 25 collaborators of Hilde Bigler. A scholar is included among the top collaborators of Hilde Bigler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hilde Bigler. Hilde Bigler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

Vaidyanathan, Sujata, Hilde Bigler, Marie‐Noëlle Bizot, et al.. (2007). Pharmacokinetics of the Oral Direct??Renin Inhibitor Aliskiren Alone and??in Combination with Irbesartan in??Renal Impairment. Clinical Pharmacokinetics. 46(8). 661–675. 56 indexed citations

Holdaas, Hallvard, Edward H. Hagen, Anders Åsberg, et al.. (2006). Evaluation of the pharmacokinetic interaction between fluvastatin XL and cyclosporine in renal transplant recipients. International Journal of Clinical Pharmacology and Therapeutics. 44(4). 163–171. 20 indexed citations

Sunkara, Gangadhar, et al.. (2003). The effect of nateglinide on the pharmacokinetics and pharmacodynamics of acenocoumarol. Current Medical Research and Opinion. 20(1). 41–48. 5 indexed citations

Galanello, Renzo, Antonio Piga, Daniele Alberti, et al.. (2003). Safety, Tolerability, and Pharmacokinetics of ICL670, a New Orally Active Iron‐Chelating Agent in Patients with Transfusion‐Dependent Iron Overload Due to β‐Thalassemia. The Journal of Clinical Pharmacology. 43(6). 565–572. 117 indexed citations

Galanello, Renzo, Antonio Piga, Daniele Alberti, et al.. (2003). Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia.. PubMed. 43(6). 565–72. 150 indexed citations

Galanello, Renzo, Antonio Piga, Daniele Alberti, et al.. (2003). Safety, Tolerability, and Pharmacokinetics of ICL670, a New Orally Active Iron-Chelating Agent in Patients with Transfusion-Dependent Iron Overload Due to β-Thalassemia. The Journal of Clinical Pharmacology. 43(6). 565–532. 10 indexed citations

Séchaud, Romain, et al.. (2002). Bioequivalence study of a valsartan tablet and a capsule formulation after single dosing in healthy volunteers using a replicated crossover design. International Journal of Clinical Pharmacology and Therapeutics. 40(1). 35–40. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact